<DOC>
	<DOCNO>NCT00684073</DOCNO>
	<brief_summary>This study design determine opioid dependent subject already receive Subutex® prefer Suboxone® tablet Subutex® tablet switch Subutex® Suboxone® . Subjects select participate study continue prescribe dose Subutex® ( buprenorphine 2 16 mg daily ) first two day study ( Day 1 Day 2 ) switch receive equivalent dose Suboxone® ( buprenorphine 2 16 mg daily ) last 3 day study ( Day 3 , Day 4 Day 5 ) . The Day 5 Visit subject 's last study visit . Upon complete study , subject continue pre-study prescribed dosage Subutex® .</brief_summary>
	<brief_title>Preference Subutex® ( Buprenorphine ) Versus Suboxone® ( Buprenorphine/Naloxone ) Opioid Dependent Patients Subutex® ( Study P05094 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subject must demonstrate willingness participate study comply procedure sign write informed consent . Subject must least ( &gt; = ) 18 year age , either sex . Subject treat opioid dependence Subutex® stable daily dose 2 mg 16 mg daily , least 6 month . Subject inject/misuse treatment Subutex® . Subject must free illicit opiate drug use assess urine test perform prior inclusion . Subject must understand able adhere dose visit schedule , agree report concomitant medication / product adverse event investigator designee . Women childbearing potential ( include woman less one year postmenopausal woman become sexually active ) must use agree use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterile ( e.g. , hysterectomy tubal ligation ) . Women childbearing potential counseled appropriate use birth control study . Women currently sexually active must agree consent use one abovementioned method become sexually active participate study . Women childbearing potential must urine pregnancy test negative result within 2 week prior inclusion ( perform control investigator designee ) . Subject eligible treatment Subutex® Suboxone® accord legal drug attachment . Subject refuse take daily dose study medication control center . Subject unable complete evaluation . Women pregnant nursing . Subject history hypersensitivity buprenorphine hydrochloride naloxone hydrochloride dihydrate excipient Subutex® Suboxone® . Subject current evidence alcohol abuse . Subject severe respiratory dysfunction , severe hepatic dysfunction , acute alcohol intoxication delirium tremens . Subject rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . Initiation increase dose , within past 7 day schedule study , treatment : benzodiazepine , depressant central nervous system : morphine derivative ( analgesic , antitussive ) , certain antidepressive agent , sedative H1 antihistamine , barbiturate , benzodiazepine , anxiolytic benzodiazepine , neuroleptic , clonidine clonidinelike agent monoamine oxidase [ MAO ] inhibitor , CYP3A4 inhibitor , CYP3A4 inducer . Subjects current evidence clinically significant hematopoietic , metabolic , cardiovascular , immunologic , neurologic , hematological , gastrointestinal , hepatic , renal , psychiatric , cerebrovascular , respiratory disease , disorder , judgment investigator , may interfere study evaluation affect subject safety . Subjects use investigational product within 30 day prior enrollment . Subjects participate another trial time . Subject intend donate blood study within 3 month study completion . Subjects exclusion period `` Fichier National de Personnes qui se Prêtent à des Recherches Biomédicales '' ( National Index Persons Participating Biomedical Researches , National Index Volunteers ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Suboxone</keyword>
	<keyword>Subutex</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Naloxone</keyword>
</DOC>